BioSystem Development

By Adam Bonislawski
Agilent Technologies and Integrated Diagnostics said this week that they have entered a strategic partnership to develop mass spec workflows for protein biomarker diagnostics.

By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has completed the acquisition of BioSystem Development for an undisclosed sum.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Agilent Technologies today announced two deals that are expected to grow its footprint in the life science space.

The firm, which makes the AssayMap platform, plans to use the funds to scale up its manufacturing capabilities, increase the speed to market of its new products, and support expansion of its product pipeline.

Agilent will integrate mass-tagged PCR primers with LC-MS to enable the rapid identification of food-borne pathogens in one deal with UC-Davis, and combine its automated liquid handling platform with BioSystem's AssayMap high-throughput micro-chromatography technology in another collaboration.

The firms are combining their respective technologies to provide a platform that they said could process hundreds of samples in three hours or less.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.